The 20th JFCR－ISCC
December 9 (Wed)- 10 (Thu), 2015
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan
The 20th JFCR-International Symposium on Cancer Chemotherapy (JFCR-ISCC) is scheduled as indicated above.
The JFCR-ISCC aims at information exchange on the latest findings of newly developing molecular-targeted anti-cancer drugs and the related topics. Molecular-targeted anti-cancer drugs have been developing prominently with global standards. Meanwhile, already launched molecular-targeted drugs have often been faced with rather quickly acquired resistance, and various challenges against the resistance are rapidly evolving. Accessing to these information is indispensable, moreover, informal exchanges of personal, very specific, or even unsuccessful experiences, are critically valuable for effective achievements of future drug development. I, as the Chairman of the JFCR-ISCC, believe the Symposium with relatively small size will provide you an excellent opportunity for such communication through personal contacts.
In the upcoming 20th JFCR-ISCC, drug resistance, immunotherapy, precision medicine and epigenetics are the focused topics. I hope the Symposium would be an excellent occasion for you to access the domestic and international developments of new anti-cancer drugs and also to meet scientists, clinicians, and drug developers. So, I sincerely welcome your participation in the Symposium.
Looking forward to seeing you in Tokyo,
Naoya Fujita, Ph.D.
Chairman, JFCR-ISCC
Center Director, Cancer Chemotherapy Center, JFCR
The 20th Symposium Program Committee
Naoya Fujita (Program Committee Chairman, Cancer Chemotherapy Center, JFCR)
Nobuaki Adachi (Daiichi Sankyo Co., Ltd.)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)
Yuko Aoki (Chugai Pharmaceutical Co., Ltd.)
Shingo Dan (Cancer Chemotherapy Center, JFCR)
Kiyohiko Hatake (Cancer Chemotherapy Center, JFCR)
Seiji Ito (Bristol-Myers K.K.)
Masao Iwata (Eisai Co., Ltd.)
Hiroshi Miyake (Takeda Pharmaceutical Co. Ltd.)
Kei Muro (Aichi Cancer Center Hospital)
Hiroyoshi Nishikawa (National Cancer Center)
Atsushi Ohtsu (National Cancer Center)
Isamu Okamoto (Kyushu University)
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR)
Kenji Suzuki (Taiho Pharmaceutical Co., Ltd.)
Kazuhito Yamamoto (Aichi Cancer Center Hospital)
December 9
11:00-13:00
Poster mounting
12:00-12:30
Committee meeting
Opening Remark
13:00-13:10
Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)
Opening remark
IA new era of immuno-oncology
Chairpersons: Stefan Sleijfer (Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands)
Hiroyoshi Nishikawa (National Cancer Center, Kashiwa)
13:10-13:50
Alan J. Korman (Bristol-Myers Squibb, Redwood City, USA)
Antitumor activity of immunomodulatory antibodies – anti-CTLA-4 and anti-PD-1
13:50-14:15
Keiya Ozawa (The University of Tokyo , Tokyo)
CD19-specific CAR (chimeric antigen receptor)-expressing T cell gene therapy for B cell malignancies
14:15-14:55
Timothy A. Chan (Memorial Sloan Kettering Cancer Center, New York, USA)
Genomic landscapes and response to immune-based therapy
14:55-15:05
Discussion
15:05-15:25
Coffee break
II Toward precision cancer medicine
Chairpersons: Anthony W. Tolcher (START, San Antonio, USA)
Atsushi Ohtsu (National Cancer Center, Kashiwa)
15:25-16:05
Lillian L. Siu (Princess Margaret Cancer Centre, Tronto, Canada)
Genomic based clinical trials – now and next generation
16:05-16:30
Katsuya Tsuchihara (National Cancer Center, Kashiwa)
A nation-wide genome prescreening program stratifying lung and gastrointestinal cancer patients, SCRUM-Japan
16:30-17:10
Stefan Sleijfer (Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands)
Liquid biopsies; potential valuable tool in drug development studies
17:10-17:20
Discussion
Poster Session
17:20-18:20
Saori Miyano (Eisai Co., Ltd., Tsukuba)
Characterization of E7090: A novel and selective FGFR inhibitor
Yusuke Ogitani (Daiichi Sankyo Co., Ltd. , Tokyo)
DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies
Takahiro Nakamura (Cancer Chemotherapy Center, JFCR, Tokyo)
Glioma stem cell-selective antitumor effect of a novel G-quadruplex ligand
Li Wang (Anaeropharma Science, Inc., Tokyo)
i-DPS (in situ Delivery and Production System): A “smart” drug delivery technology to deliver and produce immune checkpoint blockers inside hypoxic tumor
Kosei Toyoshima (Takeda Pharmaceutical Co. Ltd., Fujisawa)
Analysis of circulating tumor cells derived from advanced gastric cancer
Hiromichi Kosaka (Kyowa Hakko Kirin Co., Ltd., Suntou)
Small molecule metabolic inhibitors, compound A and the derivatives specifically inhibit the cell growth of Ewing’s sarcoma cells harbor EWS-FLI1 in vitro and in vivo
Takahiko Seki (Daiichi Sankyo Co., Ltd. , Tokyo)
Pharmacological profile of MDM2 inhibitor DS-3032b and its biomarker approach (provisional titile)
Yoshiaki Nakamura (National Cancer Center, Kashiwa)
Mechanism-based epigenetic combination therapy of gastric cancer
Takahiro Ishiguro (Chugai Pharmaceutical Co., Ltd., Tokyo)
Identification and optimization of T cell-redirecting asymmetric bispecific fully IgG antibody - Next approach to cancer immunotherapy -
Yuko Kawano (Kyushu Univ., Fukuoka)
Expression of CD44 variants in EGFR-mutation positive non-small cell lung cancer (NSCLC)
Keiichi Ota (Kyushu Univ., Fukuoka)
Induction of PD-L1 expression by the EML4–ALK oncoprotein and downstream signaling pathways in Non–Small cell lung cancer
Danbee Ha (National Cancer Center, Kashiwa)
Anergic T cells naturally present in humans are immunosuppresive
18:20-19:50
Mixer
December 10
III Targeting epigenetics for cancer therapy
Chairpersons: Timothy A. Chan (Memorial Sloan Kettering Cancer Center, New York, USA)
Tomoki Naoe (NHO Nagoya Medical Center, Nagoya)
9:00-9:25
Yutaka Kondo (Nagoya City University, Nagoya)
Clinical implications of epigenetic alterations in human tumors
9:25-10:05
Tom Heightman (Astex Pharmaceuticals, Cambridge, UK)
Discovery and development of SGI-110 (guadecitabine), a second generation hypomethylating agent with clinical efficacy
10:05-10:15
Discussion
10:15-10:35
Coffee break
Poster Discussion Session
Chairperson: Yoshikazu Sugimoto (Keio University, Tokyo)
10:35-11:35
Mentor: 1: Anthony W. Tolcher
Mentor: 2: Stefan Sleijfer
Mentor: 3: Lillian L. Siu
Luncheon Seminar
Chairperson: Kensei Yamaguchi (Cancer Institute Hospital, JFCR, Tokyo)
12:00-12:50
Teiji Takechi (Taiho Pharmaceutical Co., Ltd. , Tokyo)
TAS-102, a novel oral antitumor drug consisting of trifluridine and tipiracil hydrochloride
13:00-15:00
Poster removal
Meet-the-Expert Seminar
Chairperson: Mitsuaki Yoshida (JFCR, Tokyo)
13:00-13:50
Alice Shaw (MGH Cancer Center, Boston, USA)
Next generation ALK/ROS1 inhibitors in NSCLC
13:50-14:10
Coffee break
IV Molecular mechanisms of drug resistance and rational drug combinations
Chairpersons: Lillian L. Siu (Princess Margaret Cancer Centre, Tronto, Canada)
Isamu Okamoto (Kyushu University, Fukuoka)
14:10-14:35
Hiromichi Ebi (Kanazawa University, Kanazawa)
Combinatorial approach targeting KRAS mutant cancers
14:35-15:15
Ryan B. Corcoran (MGH Cancer Center, Boston, USA)
Targeted therapy approaches to overcome drug resistance and tumor heterogeneity
15:15-15:55
Anthony W. Tolcher (START, San Antonio, USA)
Antitumor activity in RAS-driven tumors by blocking AKT and MEK
15:55-16:05
Discussion
V New targets and drugs under clinical or preclinical investigations
Chairpersons: Ryan B. Corcoran (MGH Cancer Center, Boston, USA)
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo )
16:05-16:30
Tesshi Yamada (National Cancer Center, Tokyo)
Targeting the Wnt signaling pathway in colorectal cancer
16:30-16:55
Mikihiko Naito (National Institute of Health Sciences, Tokyo)
Protein knockdown by SNIPER compounds, inducers for target protein-selective degradation
16:55-17:05
Discussion
Closing Remark
17:05-17:20
Anthony W. Tolcher (START, San Antonio, USA)
Closing remark